E. David Crawford, MD

E. David Crawford, MD

Editor in Chief
University of Colorado, Denver

Aurora, Colorado

E. David Crawford, MD, is an internationally renowned urologist, distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford is an expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has authored many scientific articles, as well as textbook and book chapters. He is an editorial reviewer or consultant for many publications, including Urology, Journal of Urology, and the Journal of Clinical Oncology. Dr. Crawford is a member of many organizations, including the American Society of Clinical Oncology (ASCO), the American Urological Association (AUA), and the American Association for the Advancement of Science (AAAS). He is the Founder and Chairman of the Prostate Conditions Education Council, which is responsible for raising awareness and screening of millions of men for prostate health issues. He has received many awards, including the CaP Cure Annual Award for Scientific Presentation, and has twice been presented with a “Freddie Award” for best medical documentaries. He has long been recognized as one of the Best Doctors of America, and is recognized as one of the top 20 urologists in the country for men, by Men’s Health Magazine.

Articles by E. David Crawford, MD

Reversing the Downward Spiral of Aging

Fred Bartlit, a renowned trial lawyer with 60 years of experience, explains the science behind exercising to combat sarcopenia. During this discussion with E. David Crawford, MD, he summarizes the main points of his book Choosing the StrongPath: Reversing the Downward Spiral of Aging.

Read More

Screening for Prostate Cancer: PSA: Why 1.5 is the New 4

E. David Crawford, MD, argues for using PSA levels of 1.5 ng/mL as the cutoff for routine screening in primary care. He emphasizes the importance of informed decision making in the event of abnormal results, reducing unnecessary biopsies and overdiagnosis, and relying more on genomic markers for detecting significant cancers.

Read More

Join the GRU Community

- Why Join? -